1. Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection
- Author
-
Chew, K.W., Hughes, M.D., Choudhary, M.C., Deo, R., Ritz, J., Wohl, D.A., Greninger, A.L., Currier, J.S., Moser, C., Daar, E.S., Flynn, J.P., Javan, A.C., Eron, J.J., Klekotka, P., Boucau, J., Fischer II, W.A., Smith, D.M., Barczak, A.K., Li, J.Z., Crain, C.R., Regan, J., ACTIV-2/A5401 Study Team, Nirula, A., Dragavon, J.A., POSITIVES study team, and Coombs, R.W.
- Subjects
Clinical Trials and Supportive Activities ,mAbs ,Antibodies ,COVID therapies ,resistance ,Vaccine Related ,Clinical Research ,Biodefense ,Monoclonal ,Humans ,Neutralizing ,Humanized ,Lung ,COVID ,SARS-CoV-2 ,Prevention ,viral culture ,COVID-19 ,Pneumonia ,COVID-19 Drug Treatment ,Emerging Infectious Diseases ,Infectious Diseases ,Good Health and Well Being ,Pneumonia & Influenza ,POSITIVES study team ,ACTIV-2/A5401 Study Team ,Immunization ,monoclonal antibodies ,Infection ,Biotechnology - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) are among the treatments recommended for high-risk ambulatory persons with coronavirus 2019 (COVID-19). Here, we study viral culture dynamics post-treatment in a subset of participants receiving the mAb bamlanivimab in the ACTIV-2 trial (ClinicalTrials.gov: NCT04518410). Viral load by qPCR and viral culture are performed from anterior nasal swabs collected on study days 0 (day of treatment), 1, 2, 3, and 7. Treatment with mAbs results in rapid clearance of culturable virus. One day after treatment, 0 of 28 (0%) participants receiving mAbs and 16 of 39 (41%) receiving placebo still have culturable virus (p
- Published
- 2022